Fig. 2From: Randomized, placebo-controlled, adjunctive study of armodafinil for bipolar I depression: implications of novel drug design and heterogeneity of concurrent bipolar maintenance treatmentsIDS-C30 response and remission. IDS-C30 = 30-Item Inventory of Depressive Symptomatology–Clinician-RatedBack to article page